- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01870141
Psychological Distress and Type 2 Diabetes (COPEST)
Glycaemic Control, Body Weight and Psychological Distress in Type 2 Diabetes: The Role of Self-Efficacy
Increasing evidence suggests that psychological disorders play an important role in the development and worsening of type 2 diabetes (T2D). Among the spectrum of psychological disorders, there is a wide literature about the association between depression and T2D and current data show an approximately two-fold prevalence of depression in adults affected by diabetes compared to un-affected subjects. Moreover, depression in diabetic patients is associated with higher blood glucose levels, poorer adherence to therapeutic regimens (whether pharmacological or therapeutic lifestyle changes), more medical complications, and higher hospitalization rates. Nevertheless, at the best of our knowledge, the mechanism underlying the association between depression and adverse diabetes-related outcomes is currently unresolved.
Aim of this project is to assess the efficacy of a psychological treatment for diabetic patients with suboptimal level of Hemoglobin A1c. This project is a RCT that seeks to address the question if type 2 diabetic patients with suboptimal glycaemic control would benefit from a specific psychological intervention, as specified below. A total of 80 diabetic patients will be recruited and randomly assigned to two treatment arms:
- Standard diabetes care
- 24 individual sessions of psychological intervention The expected main outcome is the improvement of glycaemic control under psychological intervention in 38 weeks of follow up.
Secondary outcomes: reduction of depression and anxiety, improvement in self-efficacy, perceived interference caused by diabetes, family support and eating problems.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Several studies have reported higher level of psychological disorders in people with diabetes such as depression and anxiety. A recent meta-analysis suggests that the odds of depression in the diabetic patients is twice than in nondiabetic subjects and this difference persists even after adjustment for sex, type of diabetes or assessment method. Furthermore, depression is significantly associated with hyperglycemia. Several proposals exist to explain this association.
The aim of this project is to study the effect of a psychological intervention based on cognitive-behavioural strategies in patients with type II diabetes. The effect will be evaluate on both physiological and psychosocial parameters. The hypothesis is that a psychological intervention based on cognitive behavioural strategies increases patient's belief in his self-efficacy to succeed in diabetes care. The improvement in self-efficacy will therefore lead to improve the psychological status, i.e. depression.
Material and Methods: The investigators will perform a randomized controlled trial (RCT). A sample of 80 type 2 diabetic patients will be recruited at Endocrinology Unit of Verona Hospital during routine medical examination and then randomly assigned to intervention or control arm. In details, patients will be first recruited for participation in the study by their physician. Thereafter, patients will be approached by psychologist who will explain research and its goals. Control group will receive current standard of diabetes care. Intervention group will receive a weekly psychological intervention based on cognitive behavioural strategies. Each session will be based on self-monitoring, problem solving and goal setting. The first session will be held two weeks after the enrollment and the last one will take place at twenty-sixth week. Subjects will be given a food and physical activity diary as well as a pedometer. Study participants will weekly fill in the diary starting from 2nd session until the 19th session for a total of 18 weeks. Subjects will carry the pedometer for the same time window.
The psychological intervention comprises three phases:
PHASE 1 (1°-2° session):
- Psychological testing
- Therapeutic alliance formation
- Goal definition
PHASE 2 (3°-19°)
- Food and physical activity self-monitoring
- Identifying unhealthy behaviours and helping subject to change them
- Identifying negative beliefs and replace them with positive and healthy ones
- Providing coping strategies to stress and emotions
PHASE 3 (20°-24°)
- Reinforcing behaviour modification
- Identifying possible barriers
- Activation of personal and social resources
Outcome measures will be assessed at baseline (pre-treatment), after 26 weeks treatment (post-treatment) and at 38 weeks follow up (follow-up).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Verona, Italy, 37126
- Division of Endocrinology and Metabolic Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes diagnosed at least 1 year before enrollment
- 25 ≤ BMI ≤ 40 Kg⋅m-2
- 25 to 75 years
- HbA1c > 7,0%
Exclusion Criteria:
- Current schizophrenia/ psychotic disorders, bipolar disorders, addictive disorders, personality disorders
- Current psychotherapy
- Severe physical illness (i.e. cancer)
- Pregnancy
- Eligibility to bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psychological Intervention
Cognitive Behavioural Intervention
|
1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:
|
No Intervention: Current standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline glycosylated haemoglobin (HbA1c) at 26th and 38th weeks [mmol/mol]
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)
|
Glycosylated haemoglobin (HbA1c) is a lab test that shows the average level of blood glucose over the previous 3 months.
HbA1c is used in the present study as measure of the glycaemic control: it will be assessed at baseline (pre-treatment), after 26 weeks treatment (post-treatment) and at 38 weeks follow up (follow-up).
|
Baseline, 26 weeks (post-treatment)-38 weeks (FU)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Body Mass Index (BMI)at 26th and 38th weeks [Kg/m2]
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Body Mass Index is a measure of adiposity and is used here as anthropometric marker of life style change.
|
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline depressive symptoms at 26th and 38th weeks (BDI-II score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
The Beck Depression Inventory II is a 21-item questionnaire developed to assess the intensity of depression as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). The BDI-II items include (1) cognitive symptoms such as sadness and pessimism, (2) affective symptoms such as loss of pleasure and loss of interest, (3) somatic symptoms such as loss of energy, appetite changes and changes in sleep pattern. The BDI-II is calculated by summing the ratings for the 21 items. The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63. The measurement of outcome variables will be conducted 38 weeks after termination of the treatment (38 weeks follow up). The difference of the BDI-II scores among baseline (pretreatment), at the end of the 26 weeks treatment (post-treatment), and at 38 weeks follow up (follow-up) will be also calculated. |
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline anxiety symptoms at 26th and 38th weeks(BAI score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
The Beck Anxiety Inventory is a 21- item questionnaire developed to assess the severity of an anxiety in adult and adolescents. The items in the BAI describe the emotional, physiological and cognitive symptoms of anxiety. The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63. The decisive measurement of the outcome variables will be conducted 38 weeks after termination of the treatment (38 weeks follow up). The difference of the BDI-II scores among baseline (pretreatment), at the end of the 26 weeks treatment (post-treatment), and at 38 weeks follow up (follow-up) will be also calculated. |
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline general perceptions of diabetes at 26th and 38th weeks (MDQ Section 1 score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
The Multidimensional Diabetes Questionnaire (MDQ) was designed to provide a comprehensive assessment of diabetes-related cognitive and social factors. It includes 41 items subcategorized in three sections. The first section assesses the general perceptions of diabetes and related social support. It is comprised of three scales. These scales targets:
Responses were rated on 7-point rating scales (from 0 to 6), with higher scores indicating higher levels of perceived interference, social support and severity. |
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline family support at 26th and 38th weeks (MDQ section II score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
This section of the MDQ measures social incentives in relation to self-care activities.
The scales included in this section were designed to measure the frequency of positive reinforcing behaviour (8 items) and the frequency of non supportive behaviours (4 items).
Subjects recorded their responses on 7-point Likert scales (from 0 to 6) with higher scores indicating higher levels of positive and negative reinforcement behaviours.
|
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline Diabetes Self-Efficacy at 26th and 38th weeks (MDQ section III score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
This section of the MDQ is used to assess self-efficacy expectancies (7 items) and outcome expectancies (6 items).
The self-efficacy scale measured patients' confidence in their ability to perform behaviours specific to the diabetes self-care activities.
Responses were rated on a 0 to 100 rating scale.
The outcome expectancies scale assessed patients' perceptions of the effect of diabetes self-care behaviours on metabolic control.
Responses were rated on a 0 to 100 rating scale.
|
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
|
Change from baseline Binge-Eating Disorders at 26th and 38th weeks (BES score)
Time Frame: Baseline, 26 weeks (post-treatment)-38 weeks (FU)
|
The Binge-Eating Scale (BES) is a 16-item questionnaire developed to assess the presence of binge eating behaviour indicative of eating disorders. The BES includes questions on subjects' concerns about weight and food, inability to control urges to eat, feelings of guilt after eating and frequency of strict dieting. Each question has 3-4 separate responses assigned a numerical value. The score ranges is from 0-46 |
Baseline, 26 weeks (post-treatment)-38 weeks (FU)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Enzo Bonora, MD, Universita di Verona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CE-2212 Ago, 29 2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Cognitive-Behavioral Intervention
-
Adai Technology (Beijing) Co., Ltd.CompletedDepression | AnxietyChina
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedDiabetes Mellitus, Type 2United States
-
Treatment Research InstituteNational Institute on Drug Abuse (NIDA)Completed
-
Universidad de GranadaCompletedStress, Psychological | Vision Disorders | Self Efficacy | PsychopathySpain
-
University of California, Los AngelesNational Institute of Nursing Research (NINR)Completed
-
Rotterdam University of Applied SciencesVU University of Amsterdam; Multiple primary care physical therapy clinicsCompletedNeck PainNetherlands
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedHIV InfectionsUnited States
-
Waukesha Memorial HospitalUnknownMedication ErrorsUnited States
-
Wenzhou Medical UniversityWuhan University; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaboratorsCompletedDepression | Breast Cancer | AnxietyChina
-
Soroka University Medical CenterThe Leona M. and Harry B. Helmsley Charitable TrustCompleted